Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    30
  • sponsor
    Brian Druker
Updated on 26 July 2022
cancer
myeloid leukemia
hydroxyurea
ejection fraction
ruxolitinib
leukemia
refractory acute myeloid leukemia (aml)

Summary

This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or has not responded to treatment (refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. This study is being done to see if the combination of ruxolitinib and venetoclax works better in treating patients with acute myeloid leukemia compared to standard of care chemotherapy.

Description

PRIMARY OBJECTIVE:

I. To evaluate the maximum-tolerated dose (MTD) and assess the safety of ruxolitinib in combination with venetoclax.

SECONDARY OBJECTIVES:

I. To assess the preliminary efficacy of the ruxolitinib and venetoclax combination.

II. To estimate overall and event-free survival.

EXPLORATORY OBJECTIVES:

I. To assess in vitro kinase inhibitor sensitivity using patient bone marrow (or peripheral blood) before and after treatment with the ruxolitinib and venetoclax combination.

II. To use molecular techniques (potentially including next-generation sequencing and/or BH3 profiling) to examine the mechanisms of response versus (vs.) no response.

III. To correlate molecular features with the patient response and resistance to venetoclax combination therapies.

IV. To determine the pharmacokinetic/pharmacodynamic (PK/PD) concentrations in vivo of the dual drug combination therapy.

OUTLINE: This is a dose-escalation study of ruxolitinib.

Patients receive ruxolitinib orally (PO) twice daily (BID) and venetoclax PO once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.

After completion of study treatment, patients are followed up every 6 months.

Details
Condition Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Treatment Ruxolitinib, venetoclax
Clinical Study IdentifierNCT03874052
SponsorBrian Druker
Last Modified on26 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Ability to understand and the willingness to sign a written informed consent document
Morphologically documented relapsed/refractory acute myeloid leukemia (AML) as defined by World Health Organization (WHO) criteria after at least 1 prior therapy for AML with the exception of hydroxyurea. Patients with myelodysplastic syndrome (MDS) transformed to AML that have been treated with hypomethylating agents may be considered if they fulfill one or more of the following criteria: 1) patient has a left ventricular ejection fraction of 45% or less; 2) patient has a serum creatinine of >= 1.4 gm/dl; 3) patient is age 75 or older
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
Women must not be pregnant or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to start of study drug administration
Participants must agree to use an adequate method of contraception
Must be able to take oral medications
Creatinine clearance >= 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection
Total serum bilirubin =< 1.5 x upper limit of normal (ULN) unless thought to be due to leukemic involvement
Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) =< 3.0 x ULN unless thought to be due to leukemic involvement

Exclusion Criteria

Diagnosis of acute promyelocytic leukemia (APL, or AML M3 subtype)
Active central nervous system involvement with AML
Concurrent active malignancy with expected survival of less than 1 year. For example, candidates with treated skin cancers, prostate cancer, breast cancer, etc. without metastatic disease are candidates for therapy since their expected survival exceeds that of relapsed or refractory AML. All subjects with concurrent malignancies will be reviewed by the principal investigator (PI) prior to enrollment
Clinically significant graft versus host disease (GVHD) or active GVHD requiring initiation or escalation of treatment within 28 day screening period
Participants with rapidly progressive disease (defined by blast count doubles within 48 hours) or organ dysfunction
Clinically significant coagulation abnormality, such as disseminated intravascular coagulation
Participants who are currently receiving any other investigational agents
Known clinically significant liver disease defined as ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis
Untreated human immunodeficiency virus (HIV) or active hepatitis C detectable by polymerase chain reaction (PCR), or chronic hepatitis B (patients positive for hepatitis B core antibody who are receiving intravenous immunoglobulin [IVIG] are eligible if hepatitis [Hep]B PCR is negative)
Known history of cerebrovascular accident, myocardial infarction, or intracranial hemorrhage within 2 months of enrollment
Clinically significant surgery within 2 weeks of enrollment
Per PI discretion, active infection that is not well controlled by antibacterial or antiviral therapy
Participants with known history of tuberculosis (TB; Mycobacterium tuberculosis) are not eligible for participation. At investigator discretion, latent TB test should be performed for individuals considered to be at high-risk (e.g., immune compromised, persons that have traveled to, or emigrated from, regions with high rates of TB)
Cancer-directed therapy within 1 week prior to starting treatment, with the exception
Unwillingness to receive infusion of blood products
of hydroxyurea, which is allowed to control white blood cell count
Participant on any of the following therapies need to be discussed with the sponsor
investigator
Strong and moderate CYP3A inhibitors
Strong and moderate CYP3A inducers
Patients with known sensitivity to ruxolitinib or venetoclax
Patients with uncontrolled white blood cell count (defined as > 50 K/mm^3 not
controlled with hydroxyurea)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note